Detection of preoperative chemoradiotherapy sensitivity molecular characteristics of rectal cancer by transcriptome second generation sequencing.
10.19723/j.issn.1671-167X.2019.03.025
- Author:
Wei ZHANG
1
;
Ying Jiang YE
2
;
Xian Wen REN
3
;
Jing HUANG
4
;
Zhan Long SHEN
1
Author Information
1. Department of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China.
2. Department of Gastrointestinal Surgery, Peking University People's Hospital, Beijing 100044, China.
3. Biodynamic Optical Imaging Center, School of Life Sciences, Peking University, Beijing 100871, China.
4. Department of Immunology, Peking University School of Basic Medical Sciences, Beijing 100191, China.
- Publication Type:Journal Article
- MeSH:
Chemoradiotherapy;
Exosome Multienzyme Ribonuclease Complex;
Humans;
Neoadjuvant Therapy;
Neoplasm Staging;
RNA-Binding Proteins;
Rectal Neoplasms/therapy*;
Retrospective Studies;
Transcriptome;
Treatment Outcome
- From:
Journal of Peking University(Health Sciences)
2019;51(3):542-547
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To detect the preoperative chemoradiotherapy sensitivity molecular characteristics of rectal cancer by transcriptome second generation sequencing.
METHODS:The clinicopathological data of 30 patients with locally advanced rectal cancer were collected prospectively, including 9 indicators (general conditions, imaging data before radiotherapy and chemotherapy, pathological data of biopsy before radiotherapy and chemotherapy, and tumor differentiation degree, etc.), in order to analyze the correlation between them and tumor regression grading (TRG) after radiotherapy and chemotherapy for rectal cancer. At the same time, frozen specimens of colonoscopy biopsy before neoadjuvant therapy were collected from these 30 patients, and transcriptome second-generation sequencing was performed for bioinformatics analysis to screen out the genes that might drive the radio chemotherapy sensitivity of rectal cancer.
RESULTS:Among the 30 patients with rectal cancer, 9 had complete pathological remission, 12 had partial remission, and 9 had poor remission. The degree of pathological TRG remission after radiotherapy and chemotherapy for rectal cancer was negatively correlated with the preoperative MRI T stage (P=0.046), and positively correlated with preoperative MRI rectal cancer extravascular invasion (EMVI) (P=0.003). Transcriptome second-generation sequencing of the obtained 217 transcripts (P<0.05) for signal pathway enrichment analysis, and multiple cell signal transduction pathways related to antigen presentation could be found. The high expression of HSPA1A, HSPA1B and EXOSC2 was positively correlated with postoperative pathological remission (P<0.05). The high expression of DNMBP, WASH8P, FAM57A, and SGSM2 was positively correlated with postoperative pathological remission (P<0.05).
CONCLUSION:Preoperative NMR detection of extra-tumoral vascular invasion (EMVI-positive) in patients with rectal cancer was significantly better than that of EMVI-negative patients after chemoradiotherapy. Patients with high expressions of HSPA1A, HSPA1B and EXOSC2 had poor postoperative pathological remission, while patients with high expressions of genes, such as DMNMB, WASH8P, FAM57A, and SGSM2 had good postoperative pathological remission. Based on the molecular characteristics of rectal cancer radiotherapy and chemotherapy, attempts to block or enhance the molecular pathways associated with chemosensitivity of rectal cancer, are to be made to further explore new candidate therapeutic targets that can increase the sensitivity of radiotherapy and chemotherapy for rectal cancer.
